A one-month bridge may keep full-spectrum hemp products legal long enough for Congress to act. Action Alert!
THE TOPLINE
- A Senate proposal would delay the federal hemp-product restrictions from November 12 to December 11, 2026, but the 29-day extension is not yet law and could be removed during negotiations.
- The bipartisan Lawful Hemp Protection Act could preserve full-spectrum CBD and create a federal pathway for hemp-derived supplements, but it gives the FDA overly broad power to impose limits that could effectively eliminate healthful, non-intoxicating cannabinoid products.
- Congress should pass targeted rules against natural and synthetic intoxicating cannabinoids, adulteration, and deceptive marketing—while protecting lawful CBD products, non-intoxicating “minor” cannabinoids, and truthful supplement claims.
A federal hemp ban is still barreling toward consumers, farmers, and small businesses later this year. Congress is now offering a brief delay on that ban while more permanent fixes are considered. We need to make sure this goes in the right direction so consumers have access to health-promoting hemp and cannabinoid products.
A 29-day Bridge, Not a Victory
Sweeping bans on hemp products are set to take place on November 12, 2026. A new Senate funding proposal would delay most of these only until December 11.
That month matters, but it is not yet law. The House-passed continuing resolution contains no comparable protection, so the Senate language would have to survive bicameral negotiations and receive the president’s signature.
Senator Ted Budd (R-NC) plans to seek removal of the extension. We must urge the Senate to reject that effort and preserve the delay on the ban.
What Happens if Congress Does Nothing
As we’ve explained previously, Congress quietly enacted a near-total hemp product ban late in 2025. The new law, among other things, capped the amount of THC (the main psychoactive and intoxicating component of hemp) in hemp products to 0.4mg per container. The practical effect? The full-spectrum CBD oils that contain trace, non-psychoactive amounts of THC — the very products most consumers buy for wellness — will likely not survive this threshold. Industrial hemp seed oil, hemp protein, hemp leaf teas, and the countless supplements built on whole-plant extracts are all in the crosshairs.
A New Pathway for CBD Supplements?
The Lawful Hemp Protection Act from Representatives Andy Barr (R-KY) and Angie Craig (D-MN) offers a path forward for lawful hemp products. It would remove the looming hemp ban, raise the plant threshold from 0.3 to 1 percent total THC by dry weight, exclude synthetic or altered cannabinoids, and regulate unfinished hemp-cannabinoid ingredients.
Crucially, the bill would recognize hemp-derived cannabinoid dietary supplements and exclude them from the drug definition. That would create the federal pathway for CBD supplements and full-spectrum oils that has been missing for years. FDA currently says CBD generally cannot be marketed as a dietary supplement because it was first investigated and approved as a drug ingredient.
The FDA Blank Check
Here is the problem. The bill orders FDA to set a maximum for total cannabinoid content per serving and package and a separate maximum for every cannabinoid present. That includes CBD and naturally occurring minor cannabinoids such as cannabigerol (CBG), cannabinol (CBN), and cannabichromene (CBC). To get some perspective, there are some 120 different phytocannabinoids that have been characterized and only 5 (~4%), including THC, have been shown to have potential intoxicating effects on humans (see here and here).
Rulemaking must consider science, use data, adverse events, product form, intended use, and expert input. Yet the bill gives no meaningful floor for protecting non-intoxicating cannabinoids from an arbitrarily low ceiling. If FDA misses its 12-month deadline, interim limits apply only to total THC: 5 milligrams per oral serving and 50 milligrams per inhalable or topical serving.
This invites bureaucratic overreach, something FDA is famous for. FDA could preserve a legal category on paper while regulating products out of existence in practice. The FDA track record in protecting access to natural products is shockingly bad – why would it be any different here?
The bill would also deem a product misbranded if its label makes any claim about an effect on the body’s structure or function. That is far more restrictive than the usual supplement framework. It would call these products dietary supplements while denying the truthful, substantiated speech that helps consumers understand them. This is why we are hard at work trying to open the door to such truthful claims with both our live FDAMA suit and our soon-to-filed structure-function petition.
Why Full-Spectrum Hemp Matters
Protecting access to natural, full-spectrum hemp products has to be a top priority for natural health and freedom of choice. The human body has an endocannabinoid system (ECS), a signaling network that helps regulate pain, mood, appetite, metabolism, immunity, and brain activity. Researchers have proposed that disrupted endocannabinoid signaling may be involved in conditions as diverse as migraines, fibromyalgia, and irritable bowel syndrome.
Full-spectrum hemp preserves CBD alongside minor cannabinoids, terpenes, and trace THC. These compounds may work together through the proposed “entourage effect.”
The 0.4-milligram-per-container limit could eliminate non-intoxicating full-spectrum products simply because they contain trace THC, pushing consumers toward CBD isolates that miss out on the benefits of the full-spectrum, cannabinoid entourage effect. Congress should target synthetic intoxicants, adulterated products, and deceptive marketing without destroying access to responsibly made whole-plant hemp products.
Congress Must Use the Time Wisely
The immediate priority is clear: preserve the December 11 extension and stop the 0.4-milligram ban from taking effect while Congress works.
There is legislation already before Congress that creates a better regulatory framework in the form of the Cannabinoid Safety and Regulation Act. That bill does not give FDA the power to regulate non-intoxicating cannabinoids, just THC. It also preserves structure/function claims for CBD supplements.
The Lawful Hemp Protection Act should be amended before passage. Congress should focus FDA’s limit-setting authority on intoxicating cannabinoids, require evidence-based protections for non-intoxicating CBD and minor cannabinoids, preserve lawful structure/function claims, distinguish adult-use intoxicants from non-intoxicating supplements, and provide a workable transition period.
Consumers should not have to choose between an indiscriminate ban and a regulatory blank check. America needs rules that punish adulteration, deceptive marketing, and sales to minors while preserving access to responsibly made natural products.
Action Alert!
